MedTrace Logo

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

NCT04573556 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2022-04-05

No results posted yet for this study

Summary

The purpose of the study is to evaluate the incidence of somnolence, parasomnia, narcoleptic symptoms, and suicidal ideation/suicidal behavior after administration of lemborexant (DAYVIGO) in daily practice.

Conditions

  • Sleep Initiation and Maintenance Disorders

Interventions

DRUG

Lemborexant

Lemborexant oral tablets.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-17
Primary Completion
2022-03-17
Completion
2022-03-17

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04573556 on ClinicalTrials.gov